Clinical trial
Treg/Th17-Related Cytokine Profile and Systemic Inflammatory Indices in Differentiated Thyroid Cancer: Relationship With Clinicopathological Features
NCT07907432 is registered in ClinicalTrials.gov with Marmara University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Treg/Th17-Related Cytokine Profile and Systemic Inflammatory Indices in Differentiated Thyroid Cancer: Relationship With Clinicopathological Features
- Lead sponsor
- Marmara University
- Phase
- Observational
- Overall status
- Not yet recruiting
- Start date
- November 1, 2026
- Completion date
- October 31, 2027
- Enrollment
- 90 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
differentiated thyroid cancer (dtc), nodular goiter, papillary thyroid carcinoma, thyroid cancer, thyroid nodule
Arms
As registered; 2 arms.
-
Differentiated thyroid carcinoma
Participants undergoing elective thyroidectomy whose final histopathology shows differentiated thyroid carcinoma of papillary, follicular or oncocytic type.
-
Benign nodular goiter
Participants undergoing elective thyroidectomy for a euthyroid thyroid nodule or nodular goiter whose final histopathology is benign.
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Preoperative serum interleukin-17A concentration
Serum interleukin-17A concentration measured by ELISA in a blood sample obtained before surgery, compared between participants with differentiated thyroid carcinoma and participants with benign nodular goiter on final histopathology.
Lead sponsor's other trials
Marmara University, most recent start first.
+593 more trials See the organization page
Similar trials
Same condition (Goiter, Nodular) and phase, most recent start first.
+2 more trials See the condition page